Kymera Therapeutics, Inc.
KYMR
Classement en actions
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Prix de l'action
$114.06
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$9.38B
Changement (1 jour)
5.54%
Changement (1 an)
95.57%
Pays
US
Échange Kymera Therapeutics, Inc. (KYMR)
Catégorie
Healthcare
Bénéfices pour Kymera Therapeutics, Inc. (KYMR)
Bénéfices en Jun 2026 TTM : $-299.87M
Selon les derniers rapports financiers de Kymera Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $-299.87M. En 2023, l'entreprise a réalisé un bénéfice de $-146.96M, une augmentation par rapport à celui de 2022 qui était de $-154.81M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Kymera Therapeutics, Inc. de 2018 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-299.87M | 33.96% |
| 2024 | $-223.86M | 52.32% |
| 2023 | $-146.96M | -5.07% |
| 2022 | $-154.81M | 54.47% |
| 2021 | $-100.22M | 119.81% |
| 2020 | $-45.59M | 10.54% |
| 2019 | $-41.25M | 92.14% |
| 2018 | $-21.47M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -1,859.04% |
US
|
|
| $-3.09B | 929.44% |
US
|
|
| $-4.02B | 1,239.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -750.49% |
NL
|
